Journal of Affective Disorders

, volume 362 , pages 816-827

Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review

Sabrina Wong ¹

Gia Han Le ²

Shreya Vasudeva ³

Kayla M Teopiz ⁴

Lee Phan ⁵

Shakila Meshkat ⁶

Angela T.H. Kwan ⁷

Taeho Greg Rhee ⁸

Roger Ho ⁹

Ha Yun Choi ¹⁰

Bing Cao ¹¹

Joshua D. Rosenblat ¹²

Roger S. McIntyre ¹³

Hide authors affiliations Show authors affiliations: 13 affiliations

Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: hanny.le@mail.utoronto.ca. |

Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada. Electronic address: shreya.vasudeva@mail.utoronto.ca. |

⁴

Brain and Cognition Discovery Foundation, Toronto, Canada. Electronic address: kayla.teopiz@mail.utoronto.ca. |

⁵

Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada. Electronic address: lee.phan@uhn.ca. |

⁶

Brain and Cognition Discovery Foundation, Toronto, Canada. |

⁷

Brain and Cognition Discovery Foundation, Toronto, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Canada. Electronic address: angela.kwan@mail.utoronto.ca. |

⁸

Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA. Electronic address: taeho.rhee@yale.edu. |

⁹

Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore; Division of Life Science (LIFS), Hong Kong University of Science and Technology, Hong Kong. Electronic address: rogercmho@ust.hk.

National University of Singapore

Hong Kong University of Science and Technology

¹⁰

Brain and Cognition Discovery Foundation, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Psychiatry, Veteran Health Service Medical Center, Seoul, Republic of Korea. Electronic address: hayun.choi@utoronto.ca. |

¹¹

Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, PR China. Electronic address: bingcao@swu.edu.cn. |

¹²

Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: joshua.rosenblat@uhn.ca. |

¹³

Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: roger.mcintyre@bcdf.org. |

Publication type: Journal Article

Publication date: 2024-10-01

Elsevier

Journal of Affective Disorders

scimago Q1

wos Q1

SJR: 2.121

CiteScore: 9.5

Impact factor: 4.9

ISSN: 01650327, 15732517

DOI: 10.1016/j.jad.2024.07.030

Copy DOI

PubMed ID: 39019223

Abstract

Approximately 30 % of persons with Major Depressive Disorder (MDD) inadequately respond to conventional antidepressants. Kappa opioid receptor (KOR) antagonists, aticaprant and navacaprant, are in development as treatments for MDD. Herein, we aim to comprehensively evaluate the safety, efficacy and pharmacology of aticaprant and navacaprant for MDD.

Found

Top-30

Journals

	1 2
Pharmaceuticals	Pharmaceuticals, 2, 14.29% Pharmaceuticals 2 publications, 14.29%
Pharmacology Biochemistry and Behavior	Pharmacology Biochemistry and Behavior, 1, 7.14% Pharmacology Biochemistry and Behavior 1 publication, 7.14%
Expert Opinion on Emerging Drugs	Expert Opinion on Emerging Drugs, 1, 7.14% Expert Opinion on Emerging Drugs 1 publication, 7.14%
Journal of Headache and Pain	Journal of Headache and Pain, 1, 7.14% Journal of Headache and Pain 1 publication, 7.14%
Medicina	Medicina, 1, 7.14% Medicina 1 publication, 7.14%
FOCUS The Journal of Lifelong Learning in Psychiatry	FOCUS The Journal of Lifelong Learning in Psychiatry, 1, 7.14% FOCUS The Journal of Lifelong Learning in Psychiatry 1 publication, 7.14%
Frontiers in Psychiatry	Frontiers in Psychiatry, 1, 7.14% Frontiers in Psychiatry 1 publication, 7.14%
CNS Drugs	CNS Drugs, 1, 7.14% CNS Drugs 1 publication, 7.14%
Journal of Affective Disorders	Journal of Affective Disorders, 1, 7.14% Journal of Affective Disorders 1 publication, 7.14%
	1 2

Publishers

	1 2 3 4
Springer Nature	Springer Nature, 4, 28.57% Springer Nature 4 publications, 28.57%
MDPI	MDPI, 3, 21.43% MDPI 3 publications, 21.43%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 14.29% Cold Spring Harbor Laboratory 2 publications, 14.29%
Elsevier	Elsevier, 2, 14.29% Elsevier 2 publications, 14.29%
Taylor & Francis	Taylor & Francis, 1, 7.14% Taylor & Francis 1 publication, 7.14%
American Psychiatric Association Publishing	American Psychiatric Association Publishing, 1, 7.14% American Psychiatric Association Publishing 1 publication, 7.14%
Frontiers Media S.A.	Frontiers Media S.A., 1, 7.14% Frontiers Media S.A. 1 publication, 7.14%
	1 2 3 4

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Wong S. et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review // Journal of Affective Disorders. 2024. Vol. 362. pp. 816-827.

GOST all authors (up to 50) Copy

Wong S., Le G. H., Vasudeva S., Teopiz K. M., Phan L., Meshkat S., Kwan A. T., Rhee T. G., Ho R., Choi H. Y., Cao B., Rosenblat J. D., McIntyre R. S. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review // Journal of Affective Disorders. 2024. Vol. 362. pp. 816-827.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.jad.2024.07.030

UR - https://linkinghub.elsevier.com/retrieve/pii/S0165032724010863

TI - Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review

T2 - Journal of Affective Disorders

AU - Wong, Sabrina

AU - Le, Gia Han

AU - Vasudeva, Shreya

AU - Teopiz, Kayla M

AU - Phan, Lee

AU - Meshkat, Shakila

AU - Kwan, Angela T.H.

AU - Rhee, Taeho Greg

AU - Ho, Roger

AU - Choi, Ha Yun

AU - Cao, Bing

AU - Rosenblat, Joshua D.

AU - McIntyre, Roger S.

PY - 2024

DA - 2024/10/01

PB - Elsevier

SP - 816-827

VL - 362

PMID - 39019223

SN - 0165-0327

SN - 1573-2517

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2024_Wong,

author = {Sabrina Wong and Gia Han Le and Shreya Vasudeva and Kayla M Teopiz and Lee Phan and Shakila Meshkat and Angela T.H. Kwan and Taeho Greg Rhee and Roger Ho and Ha Yun Choi and Bing Cao and Joshua D. Rosenblat and Roger S. McIntyre},

title = {Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review},

journal = {Journal of Affective Disorders},

year = {2024},

volume = {362},

publisher = {Elsevier},

month = {oct},

url = {https://linkinghub.elsevier.com/retrieve/pii/S0165032724010863},

pages = {816--827},

doi = {10.1016/j.jad.2024.07.030}

}

Publisher

Elsevier

Journal

Journal of Affective Disorders

scimago Q1

wos Q1

SJR

2.121

CiteScore

9.5

Impact factor

4.9

ISSN

01650327 (Print)

15732517 (Electronic)